Allergies News and Research

Latest Allergies News and Research

Interferon beta-1a plus remdesivir not superior to remdesivir alone in hospitalized COVID-19 patients

Interferon beta-1a plus remdesivir not superior to remdesivir alone in hospitalized COVID-19 patients

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Formula milk trials have a high risk of bias, review finds

Formula milk trials have a high risk of bias, review finds

Small portion of COVID-19 patients infectious long-term

Small portion of COVID-19 patients infectious long-term

Drug developed at Duke is approved by FDA as only therapy for congenital athymia

Drug developed at Duke is approved by FDA as only therapy for congenital athymia

Delta SARS-CoV-2 variant does not make kids sicker than Alpha, study finds

Delta SARS-CoV-2 variant does not make kids sicker than Alpha, study finds

New Maternal and Child Health Research Institute launched to improve national health in Singapore

New Maternal and Child Health Research Institute launched to improve national health in Singapore

Covid immunity through infection or vaccination: Are they equal?

Covid immunity through infection or vaccination: Are they equal?

Allergens in breastmilk could be the key for child's immune system education and allergy prevention

Allergens in breastmilk could be the key for child's immune system education and allergy prevention

Collins’ skillful piloting helped NIH steer clear of political minefields

Collins’ skillful piloting helped NIH steer clear of political minefields

University of Washington partners with USAID to better identify and prevent future pandemics

University of Washington partners with USAID to better identify and prevent future pandemics

UTHSC receives $3.2 million to upgrade the Regional Biocontainment Laboratory

UTHSC receives $3.2 million to upgrade the Regional Biocontainment Laboratory

Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

Research reveals key differences between childhood and adult chronic spontaneous urticaria

Research reveals key differences between childhood and adult chronic spontaneous urticaria

Pediatric transplant recipients mount a more robust immune response after two COVID-19 vaccine doses

Pediatric transplant recipients mount a more robust immune response after two COVID-19 vaccine doses

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Penn scientists win 2021 Lasker Award for the discovery of therapeutic mRNA technology

Penn scientists win 2021 Lasker Award for the discovery of therapeutic mRNA technology

Further evidence of safety and efficacy of mRNA-1273 vaccine in preventing symptomatic COVID-19 and SARS-CoV-2 infection

Further evidence of safety and efficacy of mRNA-1273 vaccine in preventing symptomatic COVID-19 and SARS-CoV-2 infection

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.